Normally found genes in specific cancers seem to play a important role in disease progression.
The findings attain significance as they may offer new drug targets for blitzing tumours.The research teams—led by Stephen Elledge of Brigham and Women’s Hospital in Boston, Massachusetts, and Greg Hannon of Cold Spring Harbor Laboratory in New York—say that their findings provide an alternative approach to the traditional search for oncogenes, rogue genes that can turn normal cells into tumours.
The researchers call their approach “non-oncogene addiction” idea, which suggests that a tumour relies heavily on certain normal cell pathways, and that drugs disabling gene products in those pathways could be deadly to cancer. The two teams have even designed a method to knock down thousands of genes relatively cheaply and quickly.
According to the researchers, the method uses ‘short hairpin RNAs’ (shRNAs), pieces of RNA that can be designed to target and shut off specific genes, to target normal genes into colon cancer cells, breast cancer cells and healthy breast cells.
They have revealed that the shRNAs slow or stop the cancer cells from growing without impairing the healthy cells, something that point the way to new cancer drug targets. “It will take time and money to sort out which of these are the best drug targets, but the important thing is that we are finding them,” Elledge says.
Even though drugs against oncogene products—like Novartis’ Gleevec (imatinib) and Genentech’s Tarceva (erlotinib)—have been a welcome advance for patients with cancer, patients often develop resistance to them, says Gary Schwartz of New York’s Memorial Sloan-Kettering Cancer Center.
Advertisement
Schwartz says that early clinical trials with the drug have indicated that it may operate best in a ‘therapeutic window’ in which it is more harmful to cancer cells than to healthy cells.
Advertisement
One — the The Cancer Genome Atlas — began in December 2005, and is expected to cost 1.35 billion dollars over 9 years. The other is led by scientists at the Wellcome Trust Sanger Institute in Cambridge, UK.
Source-Eurekalert
KAV/M